蛋白酪氨酸激酶抑制剂市场规模、份额及成长分析（按类型、应用、最终用户、分销管道和地区）—产业预测，2025 年至 2032 年

2023 年全球蛋白酪氨酸激酶抑制剂市场规模为 369 亿美元，预计将从 2024 年的 390 亿美元成长到 2032 年的 607.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.7%。

蛋白酪氨酸激酶抑制剂 (TKI) 市场正在经历强劲成长，这得益于需要这些关键治疗方法的癌症和慢性病发病率上升。 TKI特异性针对参与细胞讯号传导路径的酶，对于治疗各种癌症（包括肺癌、乳癌和白血病）的个人化医疗至关重要。分子生物学和药物开发的最新趋势导致更有效和选择性的 TKI 的出现，改善了患者的治疗效果并扩大了可用治疗方法的范围。针对对抗抗药性和减少副作用的下一代抑制剂的积极研发工作使市场焕发了活力。然而，高成本和监管障碍等挑战依然存在。特别是联合治疗和创新药物输送系统等趋势预计将进一步推动市场扩张，以及全球医疗基础设施的成长。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

蛋白酪氨酸激酶抑制剂市场规模（按类型）及复合年增长率（2025-2032）

• 市场概览
• BCR-ABL蛋白酪氨酸激酶抑制剂
• 表皮生长因子受体（EGFR）蛋白酪氨酸激酶抑制剂
• 血管内皮生长因子（VEGFR）蛋白酪氨酸激酶抑制剂
• 其他的

蛋白酪氨酸激酶抑制剂市场规模（依应用划分）及复合年增长率（2025-2032）

• 市场概览
• 慢性骨髓性白血病（CML）
• 肺癌
• 乳癌
• 其他的

蛋白酪氨酸激酶抑制剂市场规模（依最终用户划分）及复合年增长率（2025-2032）

• 市场概览
• 医院
• 居家护理
• 专科诊所
• 其他的

蛋白酪氨酸激酶抑制剂市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 网路药局
• 零售药局
• 其他的

蛋白酪氨酸激酶抑制剂市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• AstraZeneca plc（UK）
• Roche Holding AG（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• Eli Lilly and Company（USA）
• Bayer AG（Germany）
• AbbVie Inc.（USA）
• Daiichi Sankyo Company, Limited（Japan）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc（GSK）（UK）
• Johnson & Johnson（USA）
• Boehringer Ingelheim International GmbH（Germany）
• Exelixis, Inc.（USA）
• Incyte Corporation（USA）
• Ascentage Pharma（China）

结论和建议

Global Tyrosine Kinase Inhibitors Market size was valued at USD 36.9 billion in 2023 and is poised to grow from USD 39.0 billion in 2024 to USD 60.77 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The Tyrosine Kinase Inhibitors (TKIs) market is experiencing robust growth, propelled by the rising incidence of cancer and chronic illnesses that necessitate these pivotal therapies. By specifically targeting enzymes involved in cell signaling pathways, TKIs are vital in personalized medicine for treating diverse cancers like lung, breast, and leukemia. Recent advancements in molecular biology and drug development have led to the emergence of more effective, selective TKIs, enhancing patient outcomes and broadening available treatments. The market is bolstered by vigorous R&D efforts aimed at next-generation inhibitors to combat resistance and reduce side effects. However, challenges such as high costs and regulatory hurdles persist. Notably, trends like combination therapies with immunotherapies and innovative drug delivery systems are expected to further drive market expansion alongside growing global healthcare infrastructure.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tyrosine Kinase Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tyrosine Kinase Inhibitors Market Segments Analysis

Global Tyrosine Kinase Inhibitors Market is segmented by Type, Application, End Users, Distribution Channel and region. Based on Type, the market is segmented into BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors and Others. Based on Application, the market is segmented into Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer and Others. Based on End Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tyrosine Kinase Inhibitors Market

The Global Tyrosine Kinase Inhibitors market is primarily propelled by the alarming increase in cancer cases worldwide, especially in prevalent forms like lung cancer, breast cancer, and leukemia. Tyrosine Kinase Inhibitors (TKIs) provide targeted therapeutic strategies by disrupting specific enzymes that contribute to the proliferation of cancer cells, rendering them more effective and desirable alternatives to conventional chemotherapy methods. This rising interest in precision medicine, along with heightened public awareness and advancements in early cancer detection, is considerably widening the patient demographic that stands to benefit from the use of TKIs, further driving market growth.

Restraints in the Global Tyrosine Kinase Inhibitors Market

Although tyrosine kinase inhibitors (TKIs) offer significant clinical advantages, their high costs present a major barrier to accessibility, particularly in developing nations and for uninsured individuals. The overall expense encompasses not only the price of the medications themselves but also the necessary diagnostic tests and continual monitoring, which can put considerable pressure on healthcare systems and impede broad adoption. Financial limitations and challenges related to reimbursement may further stifle market growth, as both payers and healthcare providers look for more cost-effective treatment options. Consequently, these factors can restrict the overall reach and utilization of TKIs in various populations.

Market Trends of the Global Tyrosine Kinase Inhibitors Market

The Global Tyrosine Kinase Inhibitors (TKIs) market is witnessing a significant trend towards the integration of combination therapies with immunotherapy, particularly alongside checkpoint inhibitors. By synergistically enhancing the immune system's tumor-targeting capabilities while simultaneously inhibiting kinase-mediated tumor growth, these innovative treatment regimens are demonstrating enhanced efficacy in early clinical trials, characterized by improved response rates and prolonged progression-free survival. As research in this area expands, the paradigm shift towards these combination approaches is poised to redefine standard oncology treatment protocols, thereby unlocking substantial growth opportunities within the TKIs market and driving an evolution in cancer care strategies globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Tyrosine Kinase Inhibitors Market Size by Type & CAGR (2025-2032)

• Market Overview
• BCR-ABL Tyrosine Kinase Inhibitor
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
• Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
• Others

Global Tyrosine Kinase Inhibitors Market Size by Application & CAGR (2025-2032)

• Market Overview
• Chronic Myeloid Leukemia (CML)
• Lung Cancer
• Breast Cancer
• Others

Global Tyrosine Kinase Inhibitors Market Size by End Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Tyrosine Kinase Inhibitors Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Global Tyrosine Kinase Inhibitors Market Size & CAGR (2025-2032)

• North America (Type, Application, End Users, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, End Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascentage Pharma (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations